Literature DB >> 20846171

A causal model of chronic obstructive pulmonary disease (COPD) risk.

Louis Anthony Tony Cox1.   

Abstract

Research on the etiology of chronic pulmonary disease (COPD), an irreversible degenerative lung disease affecting 15% to 20% of smokers, has blossomed over the past half-century. Profound new insights have emerged from a combination of in vitro and -omics studies on affected lung cell populations (including cytotoxic CD8(+) T lymphocytes, regulatory CD4(+) helper T cells, dendritic cells, alveolar macrophages and neutrophils, alveolar and bronchiolar epithelial cells, goblet cells, and fibroblasts) and extracellular matrix components (especially, elastin and collagen fibers); in vivo studies on wild-type and genetically engineered mice and other rodents; clinical investigation of cell- and molecular-level changes in asymptomatic smokers and COPD patients; genetic studies of susceptible and rapidly-progressing phenotypes (both human and animal); biomarker studies of enzyme and protein degradation products in induced sputum, bronchiolar lavage, urine, and blood; and epidemiological and clinical investigations of the time course of disease progression. To this rich mix of data, we add a relatively simple in silico computational model that incorporates recent insights into COPD disease causation and progression. Our model explains irreversible degeneration of lung tissue as resulting from a cascade of positive feedback loops: a macrophage inflammation loop, a neutrophil inflammation loop, and an alveolar epithelial cell apoptosis loop. Unrepaired damage results in clinical symptoms. The resulting model illustrates how to simplify and make more understandable the main aspects of the very complex dynamics of COPD initiation and progression, as well as how to predict the effects on risk of interventions that affect specific biological responses.
© 2010 Society for Risk Analysis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20846171     DOI: 10.1111/j.1539-6924.2010.01487.x

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  3 in total

1.  Dose-response thresholds for progressive diseases.

Authors:  Louis Anthony Tony Cox
Journal:  Dose Response       Date:  2011-10-28       Impact factor: 2.658

2.  Probing Cellular and Molecular Mechanisms of Cigarette Smoke-Induced Immune Response in the Progression of Chronic Obstructive Pulmonary Disease Using Multiscale Network Modeling.

Authors:  Zhichao Pan; Haishan Yu; Jie-Lou Liao
Journal:  PLoS One       Date:  2016-09-26       Impact factor: 3.240

Review 3.  Personalized medicine for patients with COPD: where are we?

Authors:  Frits Me Franssen; Peter Alter; Nadav Bar; Birke J Benedikter; Stella Iurato; Dieter Maier; Michael Maxheim; Fabienne K Roessler; Martijn A Spruit; Claus F Vogelmeier; Emiel Fm Wouters; Bernd Schmeck
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-07-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.